---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011350"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:36:56.541302+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Capricor Q2 2024: $11M loss, positive FDA pre-BLA meeting, DMD trial fully enrolled

## Summary
- Net loss $11.0M ($0.35/sh) in Q2 2024 vs $7.4M ($0.29) in Q2 2023; revenue $4.0M.
- Cash $29.5M at June 30, 2024 (down from $39.5M at Dec 31); raised $2.1M via ATM at $6.46/sh.
- Positive pre-BLA meeting with FDA for deramiocel; HOPE-3 Phase 3 fully enrolled (105 subjects).
- Top-line data from HOPE-3 Cohort A expected Q4 2024; 3-year HOPE-2 OLE showed +3.7 point PUL benefit.
- Cash runway into Q1 2025; added to Russell 2000/3000 indexes.

## SEC filing metadata
- accession: 0001558370-24-011350
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837024011350/0001558370-24-011350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837024011350/capr-20240807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011350
- JSON: https://secwatch.observer/filing/0001558370-24-011350.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011350.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.